CIK 0001840233
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 851623397
- Phone
- +1 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-16 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +136,500 | 136,500 | ||
| 2023-01-01 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +136,500 | 136,500 | ||
| 2022-06-15 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2022-02-22 | Huber Martin H. Jr. PRESIDENT OF R&D AND CMO | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2021-10-21 | Huber Martin H. Jr. President of R&D and CMO | Grant or award · Stock Option (right to buy) | +157,058 | 157,058 |
Page 1 of 1 · 6 trades